With Orexigen's (OREX -72%) bad news, the near-term pipeline for obesity drugs is rather thin:...

|About: Orexigen Therapeut... (OREX)|By:, SA News Editor

With Orexigen's (OREX -72%bad news, the near-term pipeline for obesity drugs is rather thin: Novo Nordisk (NVO +1.5%) and Amylin (AMLN +0.7%) look to be the next candidates to offer a new FDA-approved option for the disease, while companies like Isis Pharmaceuticals (ISIS +1.8%) and its antisense-based candidate are likely at least 10 years from market approval.